Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

The study's findings have implications for early detection and prevention of breast cancer, suggesting that chromosomal ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, ...

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine ...